Case Presentation: Severe Hemophilia A with High-Titer Inhibitor on Emicizumab Prophylaxis
Chief Complaint
32-year-old male with acute left knee hemarthrosis
History of Present Illness
- Onset & Duration: [Specify when bleeding started, progression of symptoms]
- Severity: Assess pain level (0-10), degree of swelling, functional limitation (inability to bear weight, range of motion restriction)
- Precipitating factors: Recent trauma vs. spontaneous bleed
- Prior similar episodes: Frequency of breakthrough bleeds on emicizumab, typical response to treatment
- Home management attempted: Any factor replacement or bypassing agents used before presentation
Past Medical History
- Hemophilia A: Severe (baseline FVIII <1%)
- Inhibitor status: High-titer inhibitor (specify peak Bethesda units if known)
- Current prophylaxis: Emicizumab [dose and frequency - typically 1.5 mg/kg weekly or 3 mg/kg every 2 weeks]
- Baseline annualized bleeding rate (ABR) on emicizumab: [Document pre-emicizumab vs. current]
- Joint status: Baseline arthropathy score, prior hemarthroses in affected joint
- Inhibitor history: When developed, peak titer, any prior immune tolerance induction attempts
Current Medications
- Emicizumab [specific dosing regimen]
- [Any other medications]
Physical Examination
- Vital signs: [Temperature, HR, BP - assess for hemodynamic instability]
- Left knee examination:
- Swelling: Measure circumference compared to contralateral knee
- Warmth, erythema
- Range of motion: Active and passive (degrees of flexion/extension)
- Effusion: Ballottement test
- Neurovascular status: Distal pulses, sensation, compartment assessment
Laboratory Data
- Coagulation studies:
- aPTT (will be prolonged but not interpretable on emicizumab)
- FVIII activity (not reliable on emicizumab)
- Inhibitor titer (current Bethesda units)
- CBC: Hemoglobin/hematocrit (assess for significant blood loss)
- Emicizumab level if available (though not routinely needed for acute management)
Imaging
- Point-of-care ultrasound or MRI of left knee: Confirm hemarthrosis, assess volume, rule out compartment syndrome
Assessment
32-year-old male with severe hemophilia A, high-titer inhibitor, on emicizumab prophylaxis presenting with acute left knee hemarthrosis requiring bypassing agent therapy.
Management Plan
Acute Hemarthrosis Treatment
For this patient on emicizumab with breakthrough joint bleed, use recombinant factor VIIa (rFVIIa) as first-line bypassing agent 1, 2. The 2024 ISTH guidelines recommend either single-dose 270 μg/kg or three doses of 90 μg/kg at 3-hour intervals for joint bleeding 1.
Critical safety consideration: Avoid activated prothrombin complex concentrate (aPCC) in patients on emicizumab due to boxed warning for thrombotic microangiopathy and thrombosis risk 1, 3.
- Initial dose: rFVIIa 90 μg/kg IV, repeat every 3 hours × 3 doses OR single dose 270 μg/kg
- Adjunctive therapy: Tranexamic acid 10 mg/kg IV every 6-8 hours (safe with emicizumab) 4, 3
- Joint management:
- Rest, ice, compression, elevation (RICE protocol)
- Consider arthrocentesis if tense hemarthrosis (>60 mL) to prevent chondrocyte apoptosis and chronic synovitis 5
- Avoid weight-bearing until acute bleeding controlled
Monitoring
- Clinical response: Pain reduction, decreased swelling, improved range of motion within 24-48 hours
- Hemoglobin: Check at 24 hours if significant bleeding
- Thrombotic surveillance: Given emicizumab + bypassing agent use, monitor for signs of thrombosis (though risk primarily with aPCC) 1, 6
Disposition
- Admission criteria: Hemodynamically unstable, inadequate response to initial bypassing agent, need for repeated dosing, concern for compartment syndrome
- Outpatient management: If bleeding controlled after initial treatment, close follow-up within 24-48 hours
Long-Term Considerations
Prophylaxis optimization: Assess emicizumab adherence and dosing adequacy. Current ABR on emicizumab should be near-zero 7. If recurrent breakthrough bleeds, consider:
- Dose escalation (though not standard)
- Evaluation for subclinical joint disease with imaging
- Physical therapy for joint protection
Immune tolerance induction (ITI): Discuss with patient if not previously attempted, though success rate ~70% and burdensome 2
Future bleeding episodes: Patient education on early recognition and when to use bypassing agents at home vs. seeking emergency care
Follow-Up
- Hemophilia treatment center visit within 1 week
- Reassess joint status, consider physical therapy referral
- Document breakthrough bleed in patient's bleeding log for ABR calculation